Australia: Argenta Therapeutics to raise A$7m on the ASX

Argenta Therapeutics, a pre-clinical drug development company developing therapeutics to reduce brain damage after a stroke, has lodge a prospectus to raise A$7m (US$5.4m) on the Australian Stock Exchange. It will offer 35m shares at A$0.20 per share through lead manager Alto Capital. The company, after providing for income tax for the half-year ended December…

You must be a HMI Subscriber to view this content.

Subscribe Now »